Pembrolizumab
Keytruda (pembrolizumab) is an antibody pharmaceutical. Pembrolizumab was first approved as Keytruda on 2014-09-04. It is used to treat hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease, melanoma, non-small-cell lung carcinoma, renal cell carcinoma, and squamous cell carcinoma of head and neck amongst others. The pharmaceutical is active against programmed cell death protein 1.
| Trade Name | Keytruda |
|---|---|
| Common Name | Pembrolizumab |
| ChEMBL ID | CHEMBL3137343 |
| Indication | hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, transitional cell carcinoma, ureteral neoplasms, urethral neoplasms, urinary bladder neoplasms, urologic neoplasms |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
